Table 4.
TRAIL fusion proteins.
| Name | Target Antigen | Combination | TRAIL Format | Ref. |
|---|---|---|---|---|
| scFvC54:sTRAIL | EGP2 | - | sTRAIL | [156] |
| scFv425:sTRAIL | EGFR | Iressa | sTRAIL | [157] |
| scFv425:sTRAILmR1-5 | EGFR | Cisplatin, valproic acid | DR4-specific sTRAIL mutant | [158] |
| scFv-scTRAIL | ErbB2 | - | three sTRAIL monomers (aa 95–281) |
[154] |
| Anti-MCSP:TRAIL | MCSP | Rimcazole | sTRAIL | [159] |
| scFv:G28-TRAIL | CD40 | - | TNC-TRAIL (95–281); | [160] |
| scFv:CD70-TRAIL variants | CD27 | - | TNC-sTRAIL monomer (aa 99–281). wt, DR4, and DR5-specific |
[161] |
| scFvM58-sTRAIL | MRP3 | - | sTRAIL | [162] |
| CD19L-sTRAIL | CD19 | Radiation | sTRAIL (aa 114–281) |
[163] |
| scFv62-TRAIL | Kv10.1 | Doxorubicin | Full-length TRAIL | [164] |
| ss-TR3 | Mesothelin | - | Covalent linked-TRAIL trimer (Monomer aa 91–281) | [165] |
| ABBV-621 | Human IgG1-Fc | Venetoclax (DLBCL, AML only), FOLFIRI + bevacizumab (KRAS-mutant CRC) | scTRAIL-RBD | NCT03082209 |
TCN, trimerization domain; DLBCL, diffuse large B-cell lymphoma; AML, acute myeloid leukemia; CRC, colorectal cancer; RBD, receptor-binding domain.